Aytu Biopharma, Inc. (AYTU)
2.31
+0.01
(+0.43%)
USD |
NASDAQ |
Jun 10, 16:00
2.31
0.00 (0.00%)
After-Hours: 18:12
Aytu Biopharma SG&A Expense (Quarterly) : 10.90M for March 31, 2026
SG&A Expense (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical SG&A Expense (Quarterly) Data
| Date | Value |
|---|---|
| March 31, 2026 | 10.90M |
| December 31, 2025 | 11.07M |
| September 30, 2025 | 10.25M |
| June 30, 2025 | 8.477M |
| March 31, 2025 | 9.303M |
| December 31, 2024 | 9.721M |
| September 30, 2024 | 10.78M |
| June 30, 2024 | 11.09M |
| March 31, 2024 | 11.99M |
| December 31, 2023 | 12.02M |
| September 30, 2023 | 12.39M |
| June 30, 2023 | 14.10M |
| March 31, 2023 | 19.98M |
| December 31, 2022 | 18.58M |
| September 30, 2022 | 17.42M |
| June 30, 2022 | 17.40M |
| March 31, 2022 | 17.36M |
| December 31, 2021 | 17.61M |
| September 30, 2021 | 17.51M |
| June 30, 2021 | 19.98M |
| March 31, 2021 | 12.85M |
| December 31, 2020 | 12.85M |
| September 30, 2020 | 11.49M |
| June 30, 2020 | 12.05M |
| March 31, 2020 | 9.502M |
| Date | Value |
|---|---|
| December 31, 2019 | 6.516M |
| September 30, 2019 | 5.146M |
| June 30, 2019 | 4.896M |
| March 31, 2019 | 5.376M |
| December 31, 2018 | 5.138M |
| September 30, 2018 | 3.830M |
| June 30, 2018 | 3.923M |
| March 31, 2018 | 4.638M |
| December 31, 2017 | 4.553M |
| September 30, 2017 | 4.618M |
| June 30, 2017 | 0.0278M |
| March 31, 2017 | 4.421M |
| December 31, 2016 | 3.693M |
| September 30, 2016 | 5.756M |
| June 30, 2016 | 3.155M |
| March 31, 2016 | 2.245M |
| December 31, 2015 | 1.774M |
| September 30, 2015 | 1.709M |
| March 31, 2015 | 1.088M |
| February 28, 2015 | 0.0094M |
| November 30, 2014 | 0.0153M |
| August 31, 2014 | 0.0057M |
| May 31, 2014 | 0.0051M |
| February 28, 2014 | 0.0049M |
| November 30, 2013 | 0.0066M |
SG&A Expense (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
SG&A Expense (Quarterly) Benchmarks
| Talphera, Inc. | 2.298M |
| Aquestive Therapeutics, Inc. | 10.98M |
| ANI Pharmaceuticals, Inc. | 73.66M |
| Corcept Therapeutics, Inc. | 145.36M |
| Assertio Holdings, Inc. | 11.14M |